Malarial Vaccines Market: Opportunity Analysis and Future Assessment 2020-2028
Malaria is a life-threatening disease in many regions that are tropical and subtropical in nature, which further gives the parasite to grow in an abundant population. There are around 100 countries that are in the effect of malaria currently, which most of the countries are in the African region and risk increase by the increase in traveling of the tourists in such countries. Travelers moving in the countries with ongoing local malaria transmission coming from regions of no transmission are comparatively at higher risk of malaria and consequences related due to the lack of immunity. Furthermore, the migrants moving from countries with malarial transmission staying in the malaria-free regions and returning to their residential countries to visit their relatives are similarly at significant risk because of waning or absent immunity.
Malaria is caused by the parasite such as Plasmodium. Human malaria is caused by four different species of Plasmodium: P. falciparum, P. malariae P. ovale and P. vivax. According to the WHO, in 2015, around 214 Mn cases of malaria were found globally that initiated the positive thought process of various governments to take a check on the endemic in the respective regions. Though, there was around 37% decrease in the malarial incidence globally between 2000 and 2015 with 60% deaths due to malaria in the same period of time. The increase in the prevalence of malaria in the emerging economies is expected to support the malarial vaccines market in the near future. Vaccines that can act as the prophylactic agents in malaria are to be launched in 2018 by the effective collaboration of PATH/MVI (Path Malarial vaccine initiative) and GSK that began in 2001 whose first candidate is named as RTS,S/AS01 or Mosquirix™.
The global malarial vaccines market in 2020 is estimated for more than US$ 22.7 Mn and expected to reach a value of US$ 237.2 Mn by 2028 with a significant CAGR of 34.1%.
Global malarial vaccines market is mainly dominated by
GlaxoSmithKline plc
Sanaria Inc.
Nobelpharma Co., Ltd.
Sumaya Biotech
GenVec, Inc.
GeoVax Labs, Inc.
The global malarial vaccines market is segmented on the basis of agent type, vaccine type, distribution channel, and region
On the basis of the agent type, the global malarial vaccines market can be segmented into:
Plasmodium Falciparum
Plasmodium Vivax
Plasmodium Malariae
Plasmodium Ovale
On the basis of vaccines type, the global malarial vaccines market can be segmented into:
Pre-Erythrocytic Vaccine
Erythrocytic Vaccine
Multi-Antigen Vaccine
On the basis of distribution channel, the global malarial vaccines market can be segmented into
Hospitals
Community Centers
Clinics
The global malarial vaccines market is expected to increase at a significant CAGR over the forecast period owing to the increasing prevalence and government initiatives for proper relief across the healthcare receivers.
Increasing expenditure in vaccine development in the industry is also one of the major factors, which is expected to increase the demand for the malarial vaccines market globally over the forecast period. With the increase in awareness for malarial vaccines by the various communities and the government.
On the basis of region, the global malarial vaccines market is segmented into six regions namely North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. Africa malarial vaccines market is expected to be the most dominating market throughout the forecast period. The high prevalence of the disease is expected to be one of the main factors to support the increase in the malarial vaccines market over the forecast period.
1. Global Malarial Vaccines Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Malarial Vaccines Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Malarial Vaccines Market Snapshot
2.4. Global Malarial Vaccines Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Malarial Vaccines Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Malarial Vaccines Market, By Agent Type
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Agent Type
3.1.2. BPS Analysis, By Agent Type
3.2. Market Revenue (US$Mn) Forecast, By Agent Type
3.2.1. Plasmodium Falciparum
3.2.2. Plasmodium Vivax
3.2.3. Plasmodium Malariae
3.2.4. Plasmodium Ovale
3.3. Global Malarial Vaccines Market Attractiveness Index, By Agent Type
4. Global Malarial Vaccines Market, By Vaccines Type
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Vaccines Type
4.1.2. BPS Analysis, By Vaccines Type
4.2. Market Revenue (US$Mn) Forecast, By Vaccines Type
4.2.1. Pre-Erythrocytic Vaccine
4.2.2. Erythrocytic Vaccine
4.2.3. Multi-Antigen Vaccine
4.3. Global Malarial Vaccines Market Attractiveness Index, By Vaccines Type
5. Global Malarial Vaccines Market, By Distribution Channel
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Distribution Channel
5.1.2. BPS Analysis, By Distribution Channel
5.2. Market Revenue (US$Mn) Forecast, By Distribution Channel
5.2.1. Hospitals
5.2.2. Community Centers
5.2.3. Clinics
5.3. Global Malarial Vaccines Market Attractiveness Index, By Distribution Channel
6. Global Malarial Vaccines Market, By Region
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Region
6.1.2. BPS Analysis, By Region
6.2. Market Revenue (US$Mn) Forecast, By Region
6.2.1. North America
6.2.2. Latin America
6.2.3. Europe
6.2.4. Asia Pacific
6.2.5. Middle East
6.2.6. Africa
6.3. Global Malarial Vaccines Market Attractiveness Index, By Region
7. North America Malarial Vaccines Market Analysis and Forecast, 2020–2028
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By Country
7.1.2. BPS Analysis, By Country
7.2. Market Revenue (US$Mn) Forecast, By Country
7.2.1. U.S. Malarial Vaccines Market
7.2.2. Canada Malarial Vaccines Market
7.3. North America Malarial Vaccines Market, By Agent Type
7.3.1. Plasmodium Falciparum
7.3.2. Plasmodium Vivax
7.3.3. Plasmodium Malariae
7.3.4. Plasmodium Ovale
7.4. North America Malarial Vaccines Market, By Vaccines Type
7.4.1. Pre-Erythrocytic Vaccine
7.4.2. Erythrocytic Vaccine
7.4.3. Multi-Antigen Vaccine
7.5. North America Malarial Vaccines Market, By Distribution Channel
7.5.1. Hospitals
7.5.2. Community Centers
7.5.3. Clinics
7.6. North America Malarial Vaccines Market Attractiveness Index
7.6.1. By Country
7.6.2. By Agent Type
7.6.3. By Vaccines Type
7.6.4. By Distribution Channel
8. Latin America Malarial Vaccines Market Analysis and Forecast, 2020–2028
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Country
8.1.2. BPS Analysis, By Country
8.2. Market (US$Mn) Forecast, By Country
8.2.1. Brazil Malarial Vaccines Market
8.2.2. Mexico Malarial Vaccines Market
8.2.3. Argentina Malarial Vaccines Market
8.2.4. Rest of Latin America Malarial Vaccines Market
8.3. Latin America Malarial Vaccines Market, By Agent Type
8.3.1. Plasmodium Falciparum
8.3.2. Plasmodium Vivax
8.3.3. Plasmodium Malariae
8.3.4. Plasmodium Ovale
8.4. Latin America Malarial Vaccines Market, By Vaccines Type
8.4.1. Pre-Erythrocytic Vaccine
8.4.2. Erythrocytic Vaccine
8.4.3. Multi-Antigen Vaccine
8.5. Latin America Malarial Vaccines Market, By Distribution Channel
8.5.1. Hospitals
8.5.2. Community Centers
8.5.3. Clinics
8.6. Latin America Malarial Vaccines Market Attractiveness Index
8.6.1. By Country
8.6.2. By Agent Type
8.6.3. By Vaccines Type
8.6.4. By Distribution Channel
9. Europe Malarial Vaccines Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market (US$Mn) Forecast, By Country
9.2.1. U.K. Malarial Vaccines Market
9.2.2. Germany Malarial Vaccines Market
9.2.3. Italy Malarial Vaccines Market
9.2.4. France Malarial Vaccines Market
9.2.5. Spain Malarial Vaccines Market
9.2.6. Russia Malarial Vaccines Market
9.2.7. Poland Malarial Vaccines Market
9.2.8. BENELUX Malarial Vaccines Market
9.2.9. NORDIC Malarial Vaccines Market
9.2.10. Rest of Europe Malarial Vaccines Market
9.3. Europe Malarial Vaccines Market, By Agent Type
9.3.1. Plasmodium Falciparum
9.3.2. Plasmodium Vivax
9.3.3. Plasmodium Malariae
9.3.4. Plasmodium Ovale
9.4. Europe Malarial Vaccines Market, By Vaccines Type
9.4.1. Pre-Erythrocytic Vaccine
9.4.2. Erythrocytic Vaccine
9.4.3. Multi-Antigen Vaccine
9.5. Europe Malarial Vaccines Market, By Distribution Channel
9.5.1. Hospitals
9.5.2. Community Centers
9.5.3. Clinics
9.6. Europe Malarial Vaccines Market Attractiveness Index
9.6.1. By Country
9.6.2. By Agent Type
9.6.3. By Vaccines Type
9.6.4. By Distribution Channel
10. Asia Pacific Malarial Vaccines Market Analysis and Forecast, 2020–2028
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. China Malarial Vaccines Market
10.2.2. India Malarial Vaccines Market
10.2.3. Japan Malarial Vaccines Market
10.2.4. Australia and New Zealand Malarial Vaccines Market
10.2.5. South Korea Malarial Vaccines Market
10.2.6. ASEAN Malarial Vaccines Market
10.2.7. Rest of Asia Pacific Malarial Vaccines Market
10.3. Asia Pacific Malarial Vaccines Market, By Agent Type
10.3.1. Plasmodium Falciparum
10.3.2. Plasmodium Vivax
10.3.3. Plasmodium Malariae
10.3.4. Plasmodium Ovale
10.4. Asia Pacific Malarial Vaccines Market, By Vaccines Type
10.4.1. Pre-Erythrocytic Vaccine
10.4.2. Erythrocytic Vaccine
10.4.3. Multi-Antigen Vaccine
10.5. Asia Pacific Malarial Vaccines Market, By Distribution Channel
10.5.1. Hospitals
10.5.2. Community Centers
10.5.3. Clinics
10.6. Asia Pacific Malarial Vaccines Market Attractiveness Index
10.6.1. By Country
10.6.2. By Agent Type
10.6.3. By Vaccines Type
10.6.4. By Distribution Channel
11. Middle East Malarial Vaccines Market, By Region
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. GCC Countries Malarial Vaccines Market
11.2.2. Israel Malarial Vaccines Market
11.2.3. Oman Malarial Vaccines Market
11.2.4. Rest of Middle East Malarial Vaccines Market
11.3. Middle East Malarial Vaccines Market, By Agent Type
11.3.1. Plasmodium Falciparum
11.3.2. Plasmodium Vivax
11.3.3. Plasmodium Malariae
11.3.4. Plasmodium Ovale
11.4. Middle East Malarial Vaccines Market, By Vaccines Type
11.4.1. Pre-Erythrocytic Vaccine
11.4.2. Erythrocytic Vaccine
11.4.3. Multi-Antigen Vaccine
11.5. Middle East Malarial Vaccines Market, By Distribution Channel
11.5.1. Hospitals
11.5.2. Community Centers
11.5.3. Clinics
11.6. Middle East Malarial Vaccines Market Attractiveness Index
11.6.1. By Country
11.6.2. By Agent Type
11.6.3. By Vaccines Type
11.6.4. By Distribution Channel
12. Africa Malarial Vaccines Market, By Region
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Country
12.1.2. BPS Analysis, By Country
12.2. Market (US$Mn) Forecast, By Country
12.2.1. South Africa Malarial Vaccines Market
12.2.2. Egypt Malarial Vaccines Market
12.2.3. North Africa Malarial Vaccines Market
12.2.4. Rest of Africa Malarial Vaccines Market
12.3. Africa Malarial Vaccines Market, By Agent Type
12.3.1. Plasmodium Falciparum
12.3.2. Plasmodium Vivax
12.3.3. Plasmodium Malariae
12.3.4. Plasmodium Ovale
12.4. Africa Malarial Vaccines Market, By Vaccines Type
12.4.1. Pre-Erythrocytic Vaccine
12.4.2. Erythrocytic Vaccine
12.4.3. Multi-Antigen Vaccine
12.5. Africa Malarial Vaccines Market, By Distribution Channel
12.5.1. Hospitals
12.5.2. Community Centers
12.5.3. Clinics
12.6. Africa Malarial Vaccines Market Attractiveness Index
12.6.1. By Country
12.6.2. By Agent Type
12.6.3. By Vaccines Type
12.6.4. By Distribution Channel
13. Recommendation
13.1. Market Strategy
14. Competitive Landscape
14.1. Competition Dashboard
14.2. List and Company Overview of Global Key Players
14.3. Company Profiles
14.3.1. GlaxoSmithKline plc
14.3.1.1. Company Overview
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. Key Developments
14.3.1.5. Business Strategies
14.3.2. Sanaria Inc.
14.3.3. Nobelpharma Co., Ltd.
14.3.4. Sumaya Biotech
14.3.5. GenVec, Inc.
14.3.6. GeoVax Labs, Inc.
15. Acronyms
Frequently Asked Questions
What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
The global malarial vaccines market in 2020 is estimated for more than US$ 22.7 Mn and expected to reach a value of US$ 237.2 Mn by 2028 with a significant CAGR of 34.1%.
What are the key factors driving the growth of market?
The increase in the prevalence of malaria in the emerging economies is expected to support the malarial vaccines market in the near future and increasing expenditure in vaccine development are the key factors driving the growth of market
What segments are covered in market report?
The global malarial vaccines market is segmented on the basis of agent type, vaccine type, distribution channel, and region
What are the key participating players in the market?
GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech, GenVec, Inc., GeoVax Labs, Inc. are the key participating players in the market
